Medtronic (NYSE:MDT - Free Report) had its target price upped by Citigroup from $98.00 to $99.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a buy rating on the medical technology company's stock.
Other equities analysts also recently issued research reports about the stock. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research note on Friday, June 6th. Leerink Partnrs raised Medtronic to a "strong-buy" rating in a research report on Monday, June 16th. Mizuho reduced their price target on Medtronic from $100.00 to $98.00 and set an "outperform" rating on the stock in a research report on Thursday, May 22nd. Wolfe Research raised Medtronic from an "underperform" rating to a "peer perform" rating in a research report on Monday, June 30th. Finally, Leerink Partners assumed coverage on Medtronic in a research report on Monday, June 16th. They set an "outperform" rating and a $110.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Medtronic presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.47.
View Our Latest Analysis on MDT
Medtronic Stock Up 1.2%
NYSE:MDT traded up $1.04 during trading hours on Wednesday, reaching $90.04. The company's stock had a trading volume of 472,417 shares, compared to its average volume of 6,968,038. The company has a market capitalization of $115.48 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. Medtronic has a 12 month low of $76.33 and a 12 month high of $96.25. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.42 and a current ratio of 1.85. The stock has a 50 day moving average price of $85.54 and a two-hundred day moving average price of $86.71.
Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.04. The company had revenue of $8.93 billion during the quarter, compared to the consensus estimate of $8.81 billion. Medtronic had a net margin of 13.90% and a return on equity of 14.54%. Medtronic's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.46 earnings per share. Equities analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.
Medtronic Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.71 per share. The ex-dividend date is Friday, June 27th. This is a positive change from Medtronic's previous quarterly dividend of $0.70. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.15%. Medtronic's payout ratio is 78.45%.
Institutional Investors Weigh In On Medtronic
A number of large investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Medtronic during the 4th quarter worth about $1,163,580,000. Beutel Goodman & Co Ltd. acquired a new stake in Medtronic during the 4th quarter worth about $377,169,000. Boston Partners grew its position in Medtronic by 122.8% during the 1st quarter. Boston Partners now owns 6,912,055 shares of the medical technology company's stock worth $619,460,000 after purchasing an additional 3,809,450 shares during the period. Ameriprise Financial Inc. grew its position in Medtronic by 28.8% during the 1st quarter. Ameriprise Financial Inc. now owns 15,481,028 shares of the medical technology company's stock worth $1,391,141,000 after purchasing an additional 3,461,221 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Medtronic by 42.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,059,135 shares of the medical technology company's stock worth $903,915,000 after purchasing an additional 3,017,849 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.
About Medtronic
(
Get Free Report)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories

Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.